VMET
Viamet Pharmaceuticals CorpKey Statistics
About Viamet Pharmaceuticals Corp
Viamet Pharmaceuticals Corp (VMET) is a biopharmaceutical company focused on developing novel therapeutics for serious and life-threatening diseases, particularly through its innovative drug development platform that leverages its proprietary metalloenzyme-based technology. The company aims to address unmet medical needs in areas such as fungal infections and oncology, positioning itself at the forefront of therapeutic innovation. Viamet's strategic partnerships and strong intellectual property portfolio underscore its commitment to advancing its pipeline while maximizing shareholder value. As it progresses through clinical development phases, VMET stands to play a significant role in transforming treatment paradigms within its targeted therapeutic areas.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | — |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | 0 |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Volatility is currently contracting